Aytu Biopharma (AYTU) Total Non-Current Liabilities (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Total Non-Current Liabilities data on file, last reported at $16.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $16.6 million, down 10.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.6 million (down 10.88% YoY), and the FY2025 annual result was $42.1 million, up 49.72% from the prior year.
• Total Non-Current Liabilities retreated to $16.6 million in Q1 2026 per AYTU's latest filing, from $42.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $102.1 million in Q1 2022 and troughed at $14.4 million in Q1 2024.
• A 5-year average of $50.5 million and a median of $35.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 85.37% in 2024, then jumped 97.24% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $85.8 million in 2022, then sank by 60.15% to $34.2 million in 2023, then slumped by 37.4% to $21.4 million in 2024, then soared by 97.24% to $42.2 million in 2025, then tumbled by 60.76% to $16.6 million in 2026.
• Business Quant data shows AYTU's Total Non-Current Liabilities at $16.6 million in Q1 2026, $42.2 million in Q4 2025, and $35.8 million in Q3 2025.